Testing effectiveness (Phase 2)Ended earlyNCT01495884What this trial is testingThe Myocet/Lapatinib Study. ICORG 10-03, V5Who this might be right forHer2 Positive Metastatic Breast Cancer Cancer Trials Ireland 11
Large-scale testing (Phase 3)Study completedNCT01619111What this trial is testingDETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsWho this might be right forHER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells Prof. Wolfgang Janni 105
Early research (Phase 1)Study completedNCT03455270What this trial is testingG1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerWho this might be right forCarcinoma, Ductal, BreastBreast Cancer FemaleBreast Neoplasm+4 more G1 Therapeutics, Inc. 107
Not applicableStudy completedNCT03078036What this trial is testingInternational Breast Cancer Biomarker,Standard of Care and Real World Outcomes StudyWho this might be right forBreast Cancer AstraZeneca 873
Testing effectiveness (Phase 2)Active Not RecruitingNCT05898399What this trial is testingStudy of ART6043 in Advanced/Metastatic Solid Tumors PatientsWho this might be right forAdvanced Solid TumorMetastatic Solid Tumor Artios Pharma Ltd 220
Large-scale testing (Phase 3)Study completedNCT03286842What this trial is testingTo Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.Who this might be right forHER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 Mutations AstraZeneca 256
Testing effectiveness (Phase 2)UnknownNCT02983071What this trial is testingG1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerWho this might be right forCarcinoma, Ductal, BreastBreast CancerBreast Neoplasm G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Active Not RecruitingNCT04421963What this trial is testingRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibWho this might be right forOvarian CancerBreast Cancer AstraZeneca 185